Myeloid lineage-defining markers: Difference between revisions
From haematologyetc.co.uk
(Created page with "---- <div style="width: 200px"> {| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy" | colspan="1"''|Return to previous page'' |} </div> ---- '''Table: Marker patterns that allow definite diagnosis of acute myeloid leukaemia''' <div style="width: 95%"> {| class="wikitable" style="border-style: solid; border-width...") |
No edit summary |
||
Line 21: | Line 21: | ||
|colspan="1" style = "font-size:90%; color:black;" |Definite evidence of '''monocytic''' maturation | |colspan="1" style = "font-size:90%; color:black;" |Definite evidence of '''monocytic''' maturation | ||
|colspan="1" style = "font-size:90%;"|This requires detection of at least two of: [[CD14]], [[CD11c]], [[CD64]], [[NSE]], lysozyme* | |colspan="1" style = "font-size:90%;"|This requires detection of at least two of: [[CD14]], [[CD11c]], [[CD64]], [[NSE]], lysozyme* | ||
|- | |- | ||
|} | |} |
Revision as of 14:42, 21 December 2023
Table: Marker patterns that allow definite diagnosis of acute myeloid leukaemia
Pattern 1: A myeloid lineage-defining marker pattern is present and No lineage-defining markers of T or B cells are present. | |
---|---|
There are two potential marker patterns that allow definite myeloid lineage assignment in AML | |
Definite evidence of granulocytic maturation | MPO is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes below). |
Definite evidence of monocytic maturation | This requires detection of at least two of: CD14, CD11c, CD64, NSE, lysozyme* |
Notes on interpretation of MPO positivity in MPAL
The WHO classification advises that MPO expression is assessed by its intensity of expression and includes some flexibility in interpretation. The is based on several considerations:
(1) The techniques used to detect MPO do not have the same sensitivity: immunohistochemistry > flow cytometry > enzyme-cytochemistry. This means diagnosis of MPAL may be method dependent – expressing MPO as intensity allows expression to be compared with that of normal cells detected using the same method.
(2) MPO is not fully specific for myeloid lineage in all cases: this is particularly the case when expression is uniform and dim, so an element of subjectivity is present when interpreting (particularly when detected by more sensitive techniques such as immunocytochemistry).
(3) Context of MPO may be important: Applying a threshold of >10% cells being positive for MPO may improve specificity. Detecting variability of expression level of MPO by blast cells may suggest partial maturation and support myeloid lineage origin (often together with variable light scatter). The presence of other myeloid markers may provide greater confidence that MPO is lineage specific. Similarly, be aware of common patterns of aberrancy that are associated with specific alternative diagnoses: Dim (weak) expression of MPO may be a feature of otherwise typical B-LL/LBL; Burkitt-like entities may have strong MPO staining however other investigations will confirm their nature and other myeloid markers will be absent.